Aadi Bioscience to Present at the 43rd Annual Cowen Healthcare Conference

Rhea-AI Summary

Aadi Bioscience, Inc. (NASDAQ: AADI) has announced its participation in the 43rd Annual Healthcare Conference from March 6-8, 2023, in Boston, MA. CEO Brendan Delaney will join a panel titled 'Tumor Agnostic Development' on March 8, 2023, at 9:10 AM ET. The event will be webcast live on the company's investor relations website and available for replay for 30 days. Aadi focuses on precision therapies targeting genetically-defined cancers, having received FDA approval for its drug FYARRO^® for advanced tumors. The company is also conducting the PRECISION 1 trial for tumors with specific genetic alterations.

LOS ANGELES, Feb. 22, 2023 /PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ: AADI), a commercial-stage biopharmaceutical company focused on developing and commercializing precision therapies for genetically-defined cancers with alterations in mTOR pathway genes, announced today participation at the 43^rd Annual Healthcare Conference being held March 6-8, 2023, in Boston, MA.

Brendan Delaney, Aadi Bioscience CEO, will join in a panel discussion entitled, "Tumor Agnostic Development," on Wednesday, March 8, 2023 at 9:10 AM ET.  Company management will also participate in one-on-one meetings with investors during the conference. 

The panel presentation will be webcast live on the IR pages of the Aadi Biosciences website and will be available for replay for approximately 30 days following the presentation.

About Aadi Bioscience, Inc.

Aadi is a commercial-stage biopharmaceutical company focused on precision therapies for genetically defined cancers to bring transformational therapies to cancer patients with mTOR pathway driver alterations.  Aadi received FDA approval and has commercialized FYARRO^® for the treatment of adult patients with locally advanced unresectable or metastatic malignant perivascular epithelioid cell tumor (PEComa).

Aadi has also initiated PRECISION 1, a Phase 2 tumor-agnostic registration-intended trial in mTOR inhibitor-naïve malignant solid tumors harboring TSC1 or TSC2 inactivating alterations. More information on the Company's development pipeline is available on the Aadi website at www.aadibio.com and connect with us on Twitter and LinkedIn.

Contact:

Marcy Graham 
IR@aadibio.com 

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/aadi-bioscience-to-present-at-the-43rd-annual-cowen-healthcare-conference-301752691.html

SOURCE Aadi Bioscience

FAQ

When will Aadi Bioscience participate in the 43rd Annual Healthcare Conference?

Aadi Bioscience will participate in the conference from March 6-8, 2023.

What is the focus of Aadi Bioscience's panel discussion at the conference?

The focus of Aadi Bioscience's panel is 'Tumor Agnostic Development,' scheduled for March 8, 2023.

Who will represent Aadi Bioscience at the conference?

Brendan Delaney, the CEO, will represent Aadi Bioscience at the conference.

What is FYARRO and its purpose in Aadi Bioscience's portfolio?

FYARRO^® is FDA-approved for treating adult patients with advanced malignant perivascular epithelioid cell tumors.

What is the PRECISION 1 trial initiated by Aadi Bioscience?

The PRECISION 1 trial is a Phase 2 registration-intended trial for tumors with specific genetic alterations.